C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies

Zurina Romay-Penabad, Xiaowei Liu X, Guadalupe Montiel-Manzano, Elizabeth Papalardo De Martínez, Silvia S. Pierangeli

Research output: Chapter in Book/Report/Conference proceedingConference contribution

44 Citations (Scopus)

Abstract

Recent findings indicate that complement activation - involving specifically C3 and C5 - contributes to antiphospholipid (aPL)-mediated thrombosis. Two complement effector pathways are initiated by the cleavage of C5, C5a and C5b, which leads to the formation of the C5b-9 membrane attack complex. To delineate and distinguish the role of C5a from the C5b-9 membrane attack complex seeded by C5b, we examined the in vivo effects (thrombosis) of aPL on C5a receptor-deficient (C5aR-/-) mice. C5aR-/- and C5aR+/+ mice were injected with IgM or with IgG from two different patients with APS (IgM-APS or IgG-APS) or with control IgM or IgG (IgM-NHS or IgG-NHS) twice. Complement fixing activity of the Ig fractions and anticardiolipin activity in the sera of the mice were determined by enzyme-linked immunosorbent assay. Surgical procedures to study thrombus dynamics were performed. IgM-APS but not IgG-APS fixed C1q to cardiolipin-coated plates. IgM-APS significantly enhanced thrombus size in C5aR+/+ mice compared to C5aR+/+ mice treated with IgMNHS (3198 ± 2361 μm2 versus 585 ± 460 μm2). C5aR-/- mice treated with IgM-APS showed a significant reduction in thrombi size as compared with C5aR+/+ mice (676 ± 690 μm2 versus 3198 ± 2361 μm2; P = 0.001). IgG-APS enhanced thrombus formation significantly in C5aR+/+ when compared to IgG-NHS-treated mice (3507 ± 965 μm2 versus 1321 ± 798 μm 2), and these effects were not altered in C5aR-/- mice (3400 ± 1681 μm2). The data indicate that C5aR -/- mice are protected from the thrombogenic effects of some aPL antibodies.

Original languageEnglish (US)
Title of host publicationAutoimmunity, Part D
Subtitle of host publicationAutoimmune Disease, Annus Mirabilis
Pages554-566
Number of pages13
Volume1108
DOIs
StatePublished - Jun 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1108
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Fingerprint

Anaphylatoxin C5a Receptor
Antiphospholipid Antibodies
Thrombophilia
Endothelial cells
Immunoglobulin M
Endothelial Cells
Immunoglobulin G
Complement Membrane Attack Complex
Chemical activation
Thrombosis
Immunosorbents
Cardiolipins
Cells
Activation
Mouse
Assays
Complement Activation

Keywords

  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Complement activation
  • Endothelial cells
  • Thrombosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Romay-Penabad, Z., Liu X, X., Montiel-Manzano, G., De Martínez, E. P., & Pierangeli, S. S. (2007). C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. In Autoimmunity, Part D: Autoimmune Disease, Annus Mirabilis (Vol. 1108, pp. 554-566). (Annals of the New York Academy of Sciences; Vol. 1108). https://doi.org/10.1196/annals.1422.058

C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. / Romay-Penabad, Zurina; Liu X, Xiaowei; Montiel-Manzano, Guadalupe; De Martínez, Elizabeth Papalardo; Pierangeli, Silvia S.

Autoimmunity, Part D: Autoimmune Disease, Annus Mirabilis. Vol. 1108 2007. p. 554-566 (Annals of the New York Academy of Sciences; Vol. 1108).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Romay-Penabad, Z, Liu X, X, Montiel-Manzano, G, De Martínez, EP & Pierangeli, SS 2007, C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. in Autoimmunity, Part D: Autoimmune Disease, Annus Mirabilis. vol. 1108, Annals of the New York Academy of Sciences, vol. 1108, pp. 554-566. https://doi.org/10.1196/annals.1422.058
Romay-Penabad Z, Liu X X, Montiel-Manzano G, De Martínez EP, Pierangeli SS. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. In Autoimmunity, Part D: Autoimmune Disease, Annus Mirabilis. Vol. 1108. 2007. p. 554-566. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1422.058
Romay-Penabad, Zurina ; Liu X, Xiaowei ; Montiel-Manzano, Guadalupe ; De Martínez, Elizabeth Papalardo ; Pierangeli, Silvia S. / C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Autoimmunity, Part D: Autoimmune Disease, Annus Mirabilis. Vol. 1108 2007. pp. 554-566 (Annals of the New York Academy of Sciences).
@inproceedings{3ccde2a8dc2840848728fae26d6e1fb5,
title = "C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies",
abstract = "Recent findings indicate that complement activation - involving specifically C3 and C5 - contributes to antiphospholipid (aPL)-mediated thrombosis. Two complement effector pathways are initiated by the cleavage of C5, C5a and C5b, which leads to the formation of the C5b-9 membrane attack complex. To delineate and distinguish the role of C5a from the C5b-9 membrane attack complex seeded by C5b, we examined the in vivo effects (thrombosis) of aPL on C5a receptor-deficient (C5aR-/-) mice. C5aR-/- and C5aR+/+ mice were injected with IgM or with IgG from two different patients with APS (IgM-APS or IgG-APS) or with control IgM or IgG (IgM-NHS or IgG-NHS) twice. Complement fixing activity of the Ig fractions and anticardiolipin activity in the sera of the mice were determined by enzyme-linked immunosorbent assay. Surgical procedures to study thrombus dynamics were performed. IgM-APS but not IgG-APS fixed C1q to cardiolipin-coated plates. IgM-APS significantly enhanced thrombus size in C5aR+/+ mice compared to C5aR+/+ mice treated with IgMNHS (3198 ± 2361 μm2 versus 585 ± 460 μm2). C5aR-/- mice treated with IgM-APS showed a significant reduction in thrombi size as compared with C5aR+/+ mice (676 ± 690 μm2 versus 3198 ± 2361 μm2; P = 0.001). IgG-APS enhanced thrombus formation significantly in C5aR+/+ when compared to IgG-NHS-treated mice (3507 ± 965 μm2 versus 1321 ± 798 μm 2), and these effects were not altered in C5aR-/- mice (3400 ± 1681 μm2). The data indicate that C5aR -/- mice are protected from the thrombogenic effects of some aPL antibodies.",
keywords = "Antiphospholipid antibodies, Antiphospholipid syndrome, Complement activation, Endothelial cells, Thrombosis",
author = "Zurina Romay-Penabad and {Liu X}, Xiaowei and Guadalupe Montiel-Manzano and {De Mart{\'i}nez}, {Elizabeth Papalardo} and Pierangeli, {Silvia S.}",
year = "2007",
month = "6",
doi = "10.1196/annals.1422.058",
language = "English (US)",
isbn = "157331708X",
volume = "1108",
series = "Annals of the New York Academy of Sciences",
pages = "554--566",
booktitle = "Autoimmunity, Part D",

}

TY - GEN

T1 - C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies

AU - Romay-Penabad, Zurina

AU - Liu X, Xiaowei

AU - Montiel-Manzano, Guadalupe

AU - De Martínez, Elizabeth Papalardo

AU - Pierangeli, Silvia S.

PY - 2007/6

Y1 - 2007/6

N2 - Recent findings indicate that complement activation - involving specifically C3 and C5 - contributes to antiphospholipid (aPL)-mediated thrombosis. Two complement effector pathways are initiated by the cleavage of C5, C5a and C5b, which leads to the formation of the C5b-9 membrane attack complex. To delineate and distinguish the role of C5a from the C5b-9 membrane attack complex seeded by C5b, we examined the in vivo effects (thrombosis) of aPL on C5a receptor-deficient (C5aR-/-) mice. C5aR-/- and C5aR+/+ mice were injected with IgM or with IgG from two different patients with APS (IgM-APS or IgG-APS) or with control IgM or IgG (IgM-NHS or IgG-NHS) twice. Complement fixing activity of the Ig fractions and anticardiolipin activity in the sera of the mice were determined by enzyme-linked immunosorbent assay. Surgical procedures to study thrombus dynamics were performed. IgM-APS but not IgG-APS fixed C1q to cardiolipin-coated plates. IgM-APS significantly enhanced thrombus size in C5aR+/+ mice compared to C5aR+/+ mice treated with IgMNHS (3198 ± 2361 μm2 versus 585 ± 460 μm2). C5aR-/- mice treated with IgM-APS showed a significant reduction in thrombi size as compared with C5aR+/+ mice (676 ± 690 μm2 versus 3198 ± 2361 μm2; P = 0.001). IgG-APS enhanced thrombus formation significantly in C5aR+/+ when compared to IgG-NHS-treated mice (3507 ± 965 μm2 versus 1321 ± 798 μm 2), and these effects were not altered in C5aR-/- mice (3400 ± 1681 μm2). The data indicate that C5aR -/- mice are protected from the thrombogenic effects of some aPL antibodies.

AB - Recent findings indicate that complement activation - involving specifically C3 and C5 - contributes to antiphospholipid (aPL)-mediated thrombosis. Two complement effector pathways are initiated by the cleavage of C5, C5a and C5b, which leads to the formation of the C5b-9 membrane attack complex. To delineate and distinguish the role of C5a from the C5b-9 membrane attack complex seeded by C5b, we examined the in vivo effects (thrombosis) of aPL on C5a receptor-deficient (C5aR-/-) mice. C5aR-/- and C5aR+/+ mice were injected with IgM or with IgG from two different patients with APS (IgM-APS or IgG-APS) or with control IgM or IgG (IgM-NHS or IgG-NHS) twice. Complement fixing activity of the Ig fractions and anticardiolipin activity in the sera of the mice were determined by enzyme-linked immunosorbent assay. Surgical procedures to study thrombus dynamics were performed. IgM-APS but not IgG-APS fixed C1q to cardiolipin-coated plates. IgM-APS significantly enhanced thrombus size in C5aR+/+ mice compared to C5aR+/+ mice treated with IgMNHS (3198 ± 2361 μm2 versus 585 ± 460 μm2). C5aR-/- mice treated with IgM-APS showed a significant reduction in thrombi size as compared with C5aR+/+ mice (676 ± 690 μm2 versus 3198 ± 2361 μm2; P = 0.001). IgG-APS enhanced thrombus formation significantly in C5aR+/+ when compared to IgG-NHS-treated mice (3507 ± 965 μm2 versus 1321 ± 798 μm 2), and these effects were not altered in C5aR-/- mice (3400 ± 1681 μm2). The data indicate that C5aR -/- mice are protected from the thrombogenic effects of some aPL antibodies.

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Complement activation

KW - Endothelial cells

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=34948885608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948885608&partnerID=8YFLogxK

U2 - 10.1196/annals.1422.058

DO - 10.1196/annals.1422.058

M3 - Conference contribution

C2 - 17894020

AN - SCOPUS:34948885608

SN - 157331708X

SN - 9781573317085

VL - 1108

T3 - Annals of the New York Academy of Sciences

SP - 554

EP - 566

BT - Autoimmunity, Part D

ER -